Rahul Raj and Pooja Das*

Department of ENT, Rama Medical College Hospital and Research Center, Kanpur, India

*Corresponding Author: Pooja Das, Assistant Professor, Department of ENT, Rama Medical College Hospital and Research Center, Kanpur, India.

Received: January 15, 2024; Published: February 03, 2024

Abstract

Introduction: The following study has discussed the efficacy of triamcinolone and hyaluronidase as well as its improvement in clinical features. Fibrosis of the tissue, precancerous lesions, and scarring of the tissue is caused by a persistent condition known as oral submucous fibrosis (OSMF) where buccal mucosa is the most prominent site to be affected.

Methods: The department of Otorhinolaryngology in our institution carried out a study in which sixty individuals were given injections of triamcinolone and hyaluronidase to determine the effectiveness of the drugs in treating OSMF. The study was carried out on patients who had already been diagnosed with OSMF.

Results: The bulk of the patients were ranging between 20 to 30 years with the majority falling into the former category. In comparison to the number of females, there was a preponderance of males. 48.3% of patients had symptoms for a period of less than a year. 45 percent of patients showed an increase in interincisal distance of between 1 and 5 millimeters, whereas 31 percent of patients showed no change in the distance. By the end of the 12-week follow-up period, 95% of patients showed significant improvement in mouth opening, 96.7% showed a reduction in the burning sensation, 93.3% showed a reduction in the blanching of the mucosa, and 81.7% showed a reduction in the amount of ulceration.

Conclusion: The study concludes that there is reduction in all the presenting symptoms of OSMF on treatment with triamcinolone and hyaluronidase. Moreover, statistical analysis has obtained more effective outcomes.

Keywords: Submucous Fibrosis; Triamcinolone; Hyaluronidase; Pre Cancerous; OSMF

References

1. Dionne KR., et al. “Potentially malignant disorders of the oral cavity: Current practice and future directions in the clinic and laboratory”. International Journal of Cancer 136 (2015): 503-515.
2. Chole RH., et al. “Review of drug treatment of oral submucous fibrosis”. Oral Oncology 48 (2012): 393-398.
3. Wang YY., et al. “Malignant transformation in 5071 southern Taiwanese patients with potentially malignant oral mucosal disorders”. BMC Oral Health 14 (2014): 99.
4. Zhang X and Reichart PA. “A review of betel quid chewing, oral cancer and precancer in Mainland China”. Oral Oncology 43 (2007): 424-430.
5. Tilakaratne WM., et al. “Oral submucous fibrosis: A historical perspective and a review on etiology and pathogenesis”. Oral Surgery, Oral Medicine, Oral Pathology, and Oral Radiology 122 (2016): 178-191.
6. Chattopadhyay A and Ray JG. “Molecular pathology of malignant transformation of oral submucous fibrosis”. Journal of Environmental Pathology, Toxicology, and Oncology 35 (2016): 193-205.
7. Chang MC., et al. “Cell-mediated immunity and head and neck cancer: With special emphasis on betel quid chewing habit”. Oral Oncology 41 (2005): 757-775.
8. Cox SC and Walker DM. “Oral submucous fibrosis. A review”. Australian Dental Journal 41 (1996): 294-299.
9. Tsai CC., et al. “Deficiency in collagen and fibronectin phagocytosis by human buccal mucosa fibroblasts in vitro as a possible mechanism for oral submucous fibrosis”. Journal of Oral Pathology and Medicine 28 (1999): 59-63.
10. Sadaksharam J and Mahalingam S. “Evaluation of oral pentoxifylline in the management of oral submucous fibrosis—An ultrasonographic study”. Contemporary Clinical Dentistry 8 (2017): 200-204.
11. Tilakaratne WM., et al. “Intralesional corticosteroids as a treatment for restricted mouth opening in oral submucous fibrosis”. Oral Surgery, Oral Medicine, Oral Pathology, and Oral Radiology 122 (2016): 224-231.
12. Shetty P., et al. “Efficacy of spirulina as an antioxidant adjuvant to corticosteroid injection in management of oral submucous fibrosis”. Indian Journal of Dental Research 24 (2013): 347-350.
13. Daga D., et al. “Efficacy of oral colchicine with intralesional hyaluronidase or triamcinolone acetonide in the Grade II oral submucous fibrosis”. National Journal of Maxillofacial Surgery 8 (2017): 50-54.
14. Gupta D and Sharma SC. “Oral submucous fibrosis—A new treatment regimen”. Journal of Oral and Maxillofacial Surgery 46 (1988): 830-833.
15. Daga D., et al. “Efficacy of oral colchicine with intralesional hyaluronidase or triamcinolone acetonide in the Grade II oral submucous fibrosis”. National Journal of Maxillofacial Surgery1 (2017): 50-54.
16. Singh M., et al. “Efficacy of hydrocortisone acetate/hyaluronidase vs triamcinolone acetonide/hyaluronidase in the treatment of oral submucous fibrosis”. Indian Journal of Medical Research 5 (2010): 665-669.
17. Mostafa MG., et al. “Comparison between Efficacy of Combined Use of Hyaluronidise and Triamcinolone versus Hyaluronidise, Triamcinolone Acetonide and Oral Colchicine in the Treatment of Oral Submucous Fibrosis”. Mymensingh Medical Journal 1 (2021): 79-84.
18. Lanjekar AB., et al. “Comparison of Efficacy of Topical Curcumin Gel with Triamcinolone-hyaluronidase Gel Individually and in Combination in the Treatment of Oral Submucous Fibrosis”. The Journal of Contemporary Dental Practice 1 (2020): 83-90.
19. James L., et al. “Management of Oral Submucous Fibrosis with Injection of Hyaluronidase and Dexamethasone in Grade III Oral Submucous Fibrosis: A Retrospective Study”. Journal of International Oral Health 8 (2020): 82-85.

Citation

Citation: Rahul Raj and Pooja Das. “Effectiveness of Triamcinolone and Hyaluronidase in Alleviation of Clinical Spectrum in Patients with Oral Sub Mucous Fibrosis".Acta Scientific Otolaryngology 6.3 (2024): 02-08.

Copyright

Copyright: © 2024 Rahul Raj and Pooja Das. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.